Cargando…
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
PURPOSE: The sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin may reduce the incidence of obstructive sleep apnea (OSA) in patients with type 2 diabetes (T2D) and cardiovascular (CV) disease. This analysis of VERTIS CV, the CV outcome trial for the SGLT2i ertugliflozin conducted in a si...
Autores principales: | Wojeck, Brian S., Inzucchi, Silvio E., Neeland, Ian J., Mancuso, James P., Frederich, Robert, Masiukiewicz, Urszula, Cater, Nilo B., McGuire, Darren K., Cannon, Christopher P., Yaggi, Henry Klar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212814/ https://www.ncbi.nlm.nih.gov/pubmed/35596030 http://dx.doi.org/10.1007/s11325-022-02594-2 |
Ejemplares similares
-
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022) -
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2020) -
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
por: Dagogo-Jack, Samuel, et al.
Publicado: (2023) -
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
por: Cherney, David Z.I., et al.
Publicado: (2022) -
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2022)